Saniona Seeks Partners To Secure Survival
Tough Year For Danish Biotech
CEO Thomas Feldthus's new broom is sweeping clean at Saniona with the closure of its US operations and an aim of exploiting the significant interest being shown across its pipeline programs.
You may also be interested in...
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.